570 related articles for article (PubMed ID: 19555782)
1. Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia.
Shimizu Y; Tada Y; Yamauchi M; Okamoto T; Suzuki H; Ito N; Fukumoto S; Sugimoto T; Fujita T
Bone; 2009 Oct; 45(4):814-6. PubMed ID: 19555782
[TBL] [Abstract][Full Text] [Related]
2. [Bone and Nutrition. The relationship between iron and phosphate metabolism].
Takashi Y; Fukumoto S
Clin Calcium; 2015 Jul; 25(7):1037-42. PubMed ID: 26119317
[TBL] [Abstract][Full Text] [Related]
3. Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement.
Endo I; Fukumoto S; Ozono K; Namba N; Tanaka H; Inoue D; Minagawa M; Sugimoto T; Yamauchi M; Michigami T; Matsumoto T
Bone; 2008 Jun; 42(6):1235-9. PubMed ID: 18396126
[TBL] [Abstract][Full Text] [Related]
4. Effect of intravenous saccharated ferric oxide on serum FGF23 and mineral metabolism in hemodialysis patients.
Takeda Y; Komaba H; Goto S; Fujii H; Umezu M; Hasegawa H; Fujimori A; Nishioka M; Nishi S; Fukagawa M
Am J Nephrol; 2011; 33(5):421-6. PubMed ID: 21502756
[TBL] [Abstract][Full Text] [Related]
5. FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study.
Schouten BJ; Hunt PJ; Livesey JH; Frampton CM; Soule SG
J Clin Endocrinol Metab; 2009 Jul; 94(7):2332-7. PubMed ID: 19366850
[TBL] [Abstract][Full Text] [Related]
6. Iron polymaltose-induced FGF23 elevation complicated by hypophosphataemic osteomalacia.
Schouten BJ; Doogue MP; Soule SG; Hunt PJ
Ann Clin Biochem; 2009 Mar; 46(Pt 2):167-9. PubMed ID: 19151167
[TBL] [Abstract][Full Text] [Related]
7. [Case report; A case of FGF23-related hypophosphatemic osteomalacia caused by long-term administration of saccharated ferric oxide].
Wada Y; Kinoshita Y; Taguchi M; Fukumoto S; Fujita T
Nihon Naika Gakkai Zasshi; 2011 Oct; 100(10):3031-3. PubMed ID: 22175146
[No Abstract] [Full Text] [Related]
8. The role of bone in phosphate metabolism.
Fukumoto S
Mol Cell Endocrinol; 2009 Oct; 310(1-2):63-70. PubMed ID: 18822343
[TBL] [Abstract][Full Text] [Related]
9. Fibroblast growth factor 23 and its receptors.
Yu X; White KE
Ther Apher Dial; 2005 Aug; 9(4):308-12. PubMed ID: 16076372
[TBL] [Abstract][Full Text] [Related]
10. Saccharated ferric oxide (SFO)-induced osteomalacia: in vitro inhibition by SFO of bone formation and 1,25-dihydroxy-vitamin D production in renal tubules.
Sato K; Nohtomi K; Demura H; Takeuchi A; Kobayashi T; Kazama J; Ozawa H
Bone; 1997 Jul; 21(1):57-64. PubMed ID: 9213008
[TBL] [Abstract][Full Text] [Related]
11. [A case of hypophosphatemia induced by intravenous administration of saccharated iron oxide].
Konjiki O; Fukaya S; Kanou H; Imamura T; Iwamoto T; Takasaki M
Nihon Ronen Igakkai Zasshi; 1994 Oct; 31(10):805-10. PubMed ID: 7853746
[TBL] [Abstract][Full Text] [Related]
12. FGF23 concentrations vary with disease status in autosomal dominant hypophosphatemic rickets.
Imel EA; Hui SL; Econs MJ
J Bone Miner Res; 2007 Apr; 22(4):520-6. PubMed ID: 17227222
[TBL] [Abstract][Full Text] [Related]
13. [Updates on rickets and osteomalacia: FGF23-mediated hypophosphatemic rickets/osteomalacia].
Michigami T
Clin Calcium; 2013 Oct; 23(10):1429-35. PubMed ID: 24076640
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic effects of anti-FGF23 antibodies in hypophosphatemic rickets/osteomalacia.
Aono Y; Yamazaki Y; Yasutake J; Kawata T; Hasegawa H; Urakawa I; Fujita T; Wada M; Yamashita T; Fukumoto S; Shimada T
J Bone Miner Res; 2009 Nov; 24(11):1879-88. PubMed ID: 19419316
[TBL] [Abstract][Full Text] [Related]
15. Serum FGF23 levels in normal and disordered phosphorus homeostasis.
Weber TJ; Liu S; Indridason OS; Quarles LD
J Bone Miner Res; 2003 Jul; 18(7):1227-34. PubMed ID: 12854832
[TBL] [Abstract][Full Text] [Related]
16. X-Linked Hypophosphatemia and FGF23-Related Hypophosphatemic Diseases: Prospect for New Treatment.
Kinoshita Y; Fukumoto S
Endocr Rev; 2018 Jun; 39(3):274-291. PubMed ID: 29381780
[TBL] [Abstract][Full Text] [Related]
17. Randomized trial of intravenous iron-induced hypophosphatemia.
Wolf M; Chertow GM; Macdougall IC; Kaper R; Krop J; Strauss W
JCI Insight; 2018 Dec; 3(23):. PubMed ID: 30518682
[TBL] [Abstract][Full Text] [Related]
18. A case of osteomalacia due to deranged mineral balance caused by saccharated ferric oxide and short-bowel syndrome: A case report.
Nomoto H; Miyoshi H; Nakamura A; Nagai S; Kitao N; Shimizu C; Atsumi T
Medicine (Baltimore); 2017 Sep; 96(39):e8147. PubMed ID: 28953654
[TBL] [Abstract][Full Text] [Related]
19. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women.
Wolf M; Koch TA; Bregman DB
J Bone Miner Res; 2013 Aug; 28(8):1793-803. PubMed ID: 23505057
[TBL] [Abstract][Full Text] [Related]
20. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia.
Shimada T; Mizutani S; Muto T; Yoneya T; Hino R; Takeda S; Takeuchi Y; Fujita T; Fukumoto S; Yamashita T
Proc Natl Acad Sci U S A; 2001 May; 98(11):6500-5. PubMed ID: 11344269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]